Role of Selective Cyclo-Oxygenase-2 Inhibitor Celecoxib in Canine Osteosarcoma Cell Culture


Background: Experimental studies have shown that cyclo-oxygenase-2 (Cox2) is related to the development and progression of tumors, since this enzyme is induced and expressed by cells such as macrophages, osteoblasts, activated endothelial cells, and tumor cells. The activity in tumors includes proliferation, cell transformation, tumor growth, invasion and metastasis and may play an important role in carcinogenesis of the canine osteosarcoma, since it has high expression in tissue fragments. The combination of selective Cox2 inhibitors and other treatment modalities is the basis for a new anti-cancer therapy strategy. This in vitro study exposed primary cells of five different canine osteosarcoma cultures to selective Cox2 inhibitor at increasing concentrations and times. Results: For Cox2 negative cultures, despite the absence of differences, greater sensitivity of cells to treatment was observed. For Cox2 positive cultures, a higher number of necrotic cells were observed (P ≤ 0.05), when compared with negative cultures. For exposure times with Celecoxib doses, no difference (P > 0.05) was found between the three times analyzed for living, apoptotic and apoptotic/necrotic cells. There are similarities in the values of 24 h and 48 h, with slight reduction of living cells, increasing those undergoing apoptosis and apoptosis/necrosis. There was significance for necrosis (P ≤ 0.05). In 72 hours, a significant difference was observed between the other two previous values (P ≤ 0.05). It was found for the group of 100 μML-1, that there was a numerically greater signaling for apoptosis and lower (P = 0.08) for necrosis, and this point was the onset of the pharmacodynamic phenomenon, with drop in the values for living cells and increased number of necrotic cells, with a tendency (P = 0.08) for reducing the percentage of necrotic cells for the group of 100 μML-1 when compared to that of 10 μML-1. Conclusions: For Cox2 positive and negative cultures, there was difference for necrotic cells and there was no difference between Cox2 positive and Cox2 negative groups in relation to the percentage of living cells and apoptotic and apoptotic/necrotic cells. At time of 72 hours, higher percentage of living cells, lower percentage of apoptotic cells and increased percentage of necrotic cells in relation to groups of 24 and 48 hours was observed. A tendency for reducing the percentage of necrotic cells for the group of 100 μML-1 when compared to that of the group of 10 μML-1 was observed.

Share and Cite:

P. Bersano, M. Alves, M. Gartner, A. Ferrasi, J. Lima-Neto, F. Landim, S. Vexenat, C. Alves, G. Silva and N. Rocha, "Role of Selective Cyclo-Oxygenase-2 Inhibitor Celecoxib in Canine Osteosarcoma Cell Culture," Open Journal of Pathology, Vol. 3 No. 4, 2013, pp. 144-149. doi: 10.4236/ojpathology.2013.34027.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] R. C. Straw, S. J. Withrow and B. E. Powers, “Management of Canine Appendicular Osteosarcoma,” Veterinary Clinics of North America—Small Animal Practice, Vol. 20, No. 4, 1990, pp. 1141-1161.
[2] A. S. Hammer, F. R. Weeren and S. L. Padgett, “Prognostic Factors in Dogs with Osteosarcomas of the Flat or Irregular Bones,” Journal of the American Animal Hospital Association, Vol. 31, No. 4, 1995, pp. 321-326.
[3] B. Wolfesberger, I. Walter, C. Hoelzl, J. G. Thalhamammer and M. Egerbacher, “Antioplasttic Effect of the Cyclooxygenase Inhibitor Meloxicam on Canine Osteosarcoma Cells,” Research in Veterinary Science, Vol. 80, No. 3, 2006, pp. 308-316.
[4] J. Kirpensteijn, E. P. M. Timmermans-sprang, E. V. Garderen, G. R. Rutteman, I. S. L-V. Leeuwen and J. A. Mol, “Growth Hormone 109 Gene Expression in Canine Normal Growth Plates and Spontaneous Osteosarcoma,” Molecular and Celular Endocrinology, Vol. 197, 2002, pp. 179-185.
[5] M. N. Mullins, S. E. Lana, W. S. Dernell, G. K. Ogilvie, S. J. Withrow and E. J. Ehrhant, “Ciclooxygenase-2 Expression in Canine Appendicular Osteosarcomas,” Journal of Veterinary Internal Medicine, Vol. 18, No. 6, 2004, pp. 859-865.
[6] C. Khanna, J. Khan, P. Nguyen, J. Prehn, J. Caylor, C. Yeung, J. Trepel, P. Meltzer and L. Helman, “Metastasis-Associated Differences in Gene Expression in a Murine Model of Osteosarcoma,” Cancer Research, Vol. 61, No. 9, 2001, pp. 3750-3759.
[7] W. S. Dernell, N. P. Ehrhart, R. C. Straw and D. M. Vail, “Tumor of the Skeletal System,” In: S. J. Withrow and D. M. Vail, Small Animal Clinical Oncology, 4th Edition, 2007, pp. 540-582.
[8] R. Gorlick and C. Khanna, “Osteosarcoma,” Journal of Bone and Mineral Research, Vol. 25, No. 4, 2010, pp. 683-691.
[9] G. Brasileiro Filho, “Sistema ósteo-Articular,” In: “Bogliolo Patologia,” 7th Edition, Guanabara Koogan, Rio de Janeiro, 2006, pp. 979-1035.
[10] R. I. Freshney, “Culture of Animals Cells,” 6th Edition, John Wiley & Sons, Inc., New Jersey, 2010, p. 732.
[11] P. Loukopoulos, T. O’brien, M. Ghoddusi, B. A. Mungall and W. F. Robinson, “Characterisation of Novel Canine Osteosarcoma Cell Lines Producing High Levels of Matrix Metalloproteinases,” Research in Veterinary Science, Vol. 77, No. 2, 2004, pp. 131-141.
[12] G. Finak, N. Bertos, F. Pepin, S. Sadekova, M. Souleimanova, H. Zhao, H. Chen, G. Omeroglu, S. Meterissian, A. G. Meroglu, M. Hallett and M. Park, “Stromal Gene Expression Predicts Clinical Outcome in Breast Cancer,” Nature Medicine, Vol. 14, 2008, pp. 518-527.
[13] G. Gasparini, R. Longo, R. Sarmiento and A. Morabito, “Inhibitors of Cyclo-Oxigenase 2: A New Class of Anticancer Agents?” The Lancet Oncology, Vol. 4, No. 10, 2003, pp. 605-615.
[14] G. Singh-Ranger, M. Salhab and K. Mokbel, “The Role of Cyclooxygenase-2 in Breast Cancer: Review,” Breast Cancer Res. Treat, Vol. 109, No. 2, 2008, pp. 189-198.
[15] C. Waskewich, R. D. Blumenthal, H. Li, R. Sein, D. M. Goldenberg and J. Burton, “Celecoxib Exhibits the Greatest Potency Amongst Cyclooxygenase (COX) Inhibitors for Growth Inhibition of COX-2-Negative Hematopoietic and Epithelial Cell Lines,” Cancer Research, Vol. 62, No. 7, 2002, pp. 2029-2033.
[16] S. I. Mohammed, K. N. M. Khan, R. S. Sellers, M. G. Hayek, D. B. Denicola, L. Wu, P. L. Bonney and D. W. Knapp, “Expression of Cyclooxygenase-1 and 2 Naturally-Occuring Canine Cancer,” Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 70, No. 5, 2004, pp. 479-483.
[17] D. Wang and R. N. Dubois, “Prostaglandins and Cancer,” An International Journal of Gastroenterology and Hepatology, Vol. 55, No. 1, 2006, pp. 115-122.
[18] S. Gupta, V. M. Adhami, M. Subbarayan, G. T. Maclennan, J. S. Lewin, U. O. Hafeli, P. Fu and H. Mukhtar, “Suppression of Prostate Carcinogenesis by Dietary Supplementation of Celecoxib in Transgenic Adenocarcinoma of the Mouse Prostate Model,” Cancer Research, Vol. 64, No. 9, 2004, pp. 3334-3343.
[19] O. Fantappiè, M. Solazzo, N. Lasagna, F. Platini, L. Tessitore and R. Mazzanti, “P-Glycoprotein Mediates Celecoxib-Induced Apoptosis in Multiple Drug-Resistant Cell Lines,” Cancer Research, Vol. 67, No. 10, 2007, pp. 4915-4923.
[20] S. Huang and F. A. Sinicrope, “Celecoxib-Induced Apoptosis Is Enhanced by ABT-737 and by Inhibition of Autophagy in Human Colorectal Cancer Cells,” Autophagy, Vol. 6, No. 2, 2010, pp. 256-269.
[21] S. Arico, S. Pattingre, C. Bauvy, P. Gane, A. Barbat, P. Codogno and E. Ogier-denis, “Celecoxib Induces Apoptosis by Inhibiting 3-Phosphoinositide-Dependent Protein Kinase-1 Activity in the Human Colon Cancer HT-29 Cell Line,” The Journal of Biological Chemistry, Vol. 277, No. 31, 2002, pp. 27613-27621.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.